Header Logo

Connection

Joan Merrill to Humans

Back to Details
This is a "connection" page, showing publications Joan Merrill has written about Humans.
Joan Merrill
Connection Strength
2.782
Humans
  1. Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. N Engl J Med. 2022 03 17; 386(11):1034-1045.
    View in: PubMed
    Score: 0.046
  2. Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus. Rheumatology (Oxford). 2021 11 03; 60(11):5379-5389.
    View in: PubMed
    Score: 0.045
  3. SARS-CoV-2 vaccines in patients with SLE. Lupus Sci Med. 2021 03; 8(1).
    View in: PubMed
    Score: 0.043
  4. Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study. Rheumatology (Oxford). 2020 10 01; 59(10):2930-2938.
    View in: PubMed
    Score: 0.041
  5. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020 10; 16(10):581-589.
    View in: PubMed
    Score: 0.041
  6. Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity. Health Qual Life Outcomes. 2019 Jun 07; 17(1):99.
    View in: PubMed
    Score: 0.038
  7. A double-blind, randomized, placebo-controlled, phase II trial of baricitinib for systemic lupus erythematosus: how to optimize lupus trials to examine effects on cutaneous lupus erythematosus. Br J Dermatol. 2019 05; 180(5):964-965.
    View in: PubMed
    Score: 0.037
  8. Measuring disease activity in SLE is an ongoing struggle. Nat Rev Rheumatol. 2019 04; 15(4):194-195.
    View in: PubMed
    Score: 0.037
  9. The Spectrum of Health Domains Important to Lupus Patients Early Development of a Disease Activity Patient Reported Outcome. Bull Hosp Jt Dis (2013). 2019 Mar; 77(2):92-98.
    View in: PubMed
    Score: 0.037
  10. Comparison of the Lupus Foundation of America-Rapid Evaluation of Activity in Lupus to More Complex Disease Activity Instruments As Evaluated by Clinical Investigators or Real-World Clinicians. Arthritis Care Res (Hoboken). 2018 07; 70(7):1058-1063.
    View in: PubMed
    Score: 0.035
  11. New Trials in Lupus and where Are we Going. Curr Rheumatol Rep. 2018 05 03; 20(6):34.
    View in: PubMed
    Score: 0.035
  12. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (SLE): results from a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis. 2018 06; 77(6):883-889.
    View in: PubMed
    Score: 0.035
  13. Efficacy and Safety of Atacicept in Patients With Systemic Lupus Erythematosus: Results of a Twenty-Four-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm, Phase IIb Study. Arthritis Rheumatol. 2018 02; 70(2):266-276.
    View in: PubMed
    Score: 0.034
  14. The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017 06; 69(6):1257-1266.
    View in: PubMed
    Score: 0.033
  15. Prognostic significance of repeat biopsy in lupus nephritis: Histopathologic worsening and a short time between biopsies is associated with significantly increased risk for end stage renal disease and death. Clin Immunol. 2017 12; 185:3-9.
    View in: PubMed
    Score: 0.032
  16. Impact of heart rate variability, a marker for cardiac health, on lupus disease activity. Arthritis Res Ther. 2016 09 02; 18:197.
    View in: PubMed
    Score: 0.031
  17. Why, why, why de-lupus (does so badly in clinical trials). Expert Rev Clin Immunol. 2016; 12(2):95-8.
    View in: PubMed
    Score: 0.030
  18. Efficacy and safety of subcutaneous tabalumab, a monoclonal antibody to B-cell activating factor, in patients with systemic lupus erythematosus: results from ILLUMINATE-2, a 52-week, phase III, multicentre, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Feb; 75(2):332-40.
    View in: PubMed
    Score: 0.029
  19. Connective tissue diseases: Is SLE many single-organ diseases or an overlapping spectrum? Nat Rev Rheumatol. 2015 Jul; 11(7):385-6.
    View in: PubMed
    Score: 0.028
  20. A 2014 update on the management of patients with systemic lupus erythematosus. Semin Arthritis Rheum. 2014 Oct; 44(2):e1-2.
    View in: PubMed
    Score: 0.027
  21. How should lupus flares be measured? Deconstruction of the safety of estrogen in lupus erythematosus national assessment-systemic lupus erythematosus disease activity index flare index. Rheumatology (Oxford). 2014 Dec; 53(12):2175-81.
    View in: PubMed
    Score: 0.026
  22. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study. Arthritis Rheumatol. 2014 Feb; 66(2):379-89.
    View in: PubMed
    Score: 0.026
  23. Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys. Nat Rev Rheumatol. 2014 Jan; 10(1):23-34.
    View in: PubMed
    Score: 0.025
  24. Top 10 things to know about lupus activity measures. Curr Rheumatol Rep. 2013 Jun; 15(6):334.
    View in: PubMed
    Score: 0.025
  25. Co-stimulatory molecules as targets for treatment of lupus. Clin Immunol. 2013 Sep; 148(3):369-75.
    View in: PubMed
    Score: 0.025
  26. Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus. Arthritis Rheum. 2012 Oct; 64(10):3364-73.
    View in: PubMed
    Score: 0.024
  27. Treatment of systemic lupus erythematosus: a 2012 update. Bull NYU Hosp Jt Dis. 2012; 70(3):172-6.
    View in: PubMed
    Score: 0.023
  28. Autoantibodies as biomarkers for the prediction of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1726-32.
    View in: PubMed
    Score: 0.022
  29. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon a monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov; 70(11):1905-13.
    View in: PubMed
    Score: 0.022
  30. Ending the 50-year drought of FDA drug approval for SLE. Bull NYU Hosp Jt Dis. 2011; 69(3):238-42.
    View in: PubMed
    Score: 0.021
  31. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2010 Oct; 62(10):3077-87.
    View in: PubMed
    Score: 0.021
  32. Rituximab: wanted dead or alive... Arthritis Rheum. 2010 Aug; 62(8):2188-91.
    View in: PubMed
    Score: 0.020
  33. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 Jan; 62(1):222-33.
    View in: PubMed
    Score: 0.020
  34. Bone marrow edema is the most specific finding for rheumatoid arthritis (RA) on noncontrast magnetic resonance imaging of the hands and wrists: a comparison of patients with RA and healthy controls. J Rheumatol. 2010 Feb; 37(2):265-74.
    View in: PubMed
    Score: 0.020
  35. What was wrong and might now go right with clinical trials for lupus? Curr Rheumatol Rep. 2009 Aug; 11(4):235-7.
    View in: PubMed
    Score: 0.019
  36. New directions in the treatment of systemic lupus erythematosus. Curr Med Res Opin. 2009 Jun; 25(6):1501-14.
    View in: PubMed
    Score: 0.019
  37. Connective tissue diseases: What does the death of Riquent hold for the future of SLE? Nat Rev Rheumatol. 2009 Jun; 5(6):306-7.
    View in: PubMed
    Score: 0.019
  38. Clinical trials for lupus--are we there yet? Bull NYU Hosp Jt Dis. 2009; 67(3):267-70.
    View in: PubMed
    Score: 0.018
  39. Is individualized medicine on the horizon for lupus? Curr Rheumatol Rep. 2008 Aug; 10(4):257-8.
    View in: PubMed
    Score: 0.018
  40. Antiphospholipid syndrome: what's new in understanding antiphospholipid antibody-related stroke? Curr Rheumatol Rep. 2006 Jun; 8(3):159-61.
    View in: PubMed
    Score: 0.015
  41. The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis. Curr Rheumatol Rep. 2006 Apr; 8(2):100-8.
    View in: PubMed
    Score: 0.015
  42. Do antiphospholipid antibodies develop for a purpose? Curr Rheumatol Rep. 2006 Apr; 8(2):109-13.
    View in: PubMed
    Score: 0.015
  43. Catastrophic antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2006 Feb; 2(2):81-9.
    View in: PubMed
    Score: 0.015
  44. DHEA supplementation: the claims in perspective. Cleve Clin J Med. 2005 Nov; 72(11):965-6, 968, 970-1 passim.
    View in: PubMed
    Score: 0.015
  45. The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol. 2005 Oct; 19(5):709-26.
    View in: PubMed
    Score: 0.015
  46. A lupus drug and FDA approval. Science. 2005 Apr 22; 308(5721):497; author reply 497.
    View in: PubMed
    Score: 0.014
  47. Emergence of targeted immune therapies for systemic lupus. Expert Opin Emerg Drugs. 2005 Feb; 10(1):53-65.
    View in: PubMed
    Score: 0.014
  48. BLyS antagonists and peptide tolerance induction. Lupus. 2005; 14(3):204-9.
    View in: PubMed
    Score: 0.014
  49. Genetics of antiphospholipid syndrome. Curr Rheumatol Rep. 2004 Dec; 6(6):458-62.
    View in: PubMed
    Score: 0.014
  50. Diagnosis of the antiphospholipid syndrome: how far to go? Curr Rheumatol Rep. 2004 Dec; 6(6):469-72.
    View in: PubMed
    Score: 0.014
  51. Challenges in bringing the bench to bedside in drug development for SLE. Nat Rev Drug Discov. 2004 Dec; 3(12):1036-46.
    View in: PubMed
    Score: 0.014
  52. LJP 1082: a toleragen for Hughes syndrome. Lupus. 2004; 13(5):335-8.
    View in: PubMed
    Score: 0.013
  53. Antibodies and clinical features of the antiphospholipid syndrome as criteria for systemic lupus erythematosus. Lupus. 2004; 13(11):869-76.
    View in: PubMed
    Score: 0.013
  54. The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis. Curr Rheumatol Rep. 2003 Oct; 5(5):401-6.
    View in: PubMed
    Score: 0.013
  55. Dehydroepiandrosterone, a sex steroid metabolite in development for systemic lupus erythematosus. Expert Opin Investig Drugs. 2003 Jun; 12(6):1017-25.
    View in: PubMed
    Score: 0.012
  56. Measuring disease activity in systemic lupus: progress and problems. J Rheumatol. 2002 Nov; 29(11):2256-7.
    View in: PubMed
    Score: 0.012
  57. Regulation of the vasculature: clues from lupus. Curr Opin Rheumatol. 2002 Sep; 14(5):504-9.
    View in: PubMed
    Score: 0.012
  58. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2022 Nov; 74(11):1822-1828.
    View in: PubMed
    Score: 0.012
  59. Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature. Ann Rheum Dis. 2022 10; 81(10):1428-1437.
    View in: PubMed
    Score: 0.012
  60. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials. Ann Rheum Dis. 2022 07; 81(7):962-969.
    View in: PubMed
    Score: 0.012
  61. Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2022 08; 81(8):1143-1150.
    View in: PubMed
    Score: 0.011
  62. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials. Ann Rheum Dis. 2022 07; 81(7):951-961.
    View in: PubMed
    Score: 0.011
  63. Prediction of Hospitalizations in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Care Res (Hoboken). 2022 04; 74(4):638-647.
    View in: PubMed
    Score: 0.011
  64. Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. Arthritis Care Res (Hoboken). 2022 03; 74(3):420-426.
    View in: PubMed
    Score: 0.011
  65. Dual antibody reactivity to beta2-glycoprotein I and protein S: increased association with thrombotic events in the antiphospholipid syndrome. Lupus. 2002; 11(4):215-20.
    View in: PubMed
    Score: 0.011
  66. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Ann Rheum Dis. 2022 03; 81(3):370-378.
    View in: PubMed
    Score: 0.011
  67. Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis Rheumatol. 2021 12; 73(12):2293-2302.
    View in: PubMed
    Score: 0.011
  68. Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care Res (Hoboken). 2021 12; 73(12):1789-1795.
    View in: PubMed
    Score: 0.011
  69. Lower vitamin D is associated with metabolic syndrome and insulin resistance in systemic lupus: data from an international inception cohort. Rheumatology (Oxford). 2021 10 02; 60(10):4737-4747.
    View in: PubMed
    Score: 0.011
  70. Appropriate management of antiphospholipid-related pregnancy in women without lupus who have low titer autoantibodies. Curr Rheumatol Rep. 2001 Aug; 3(4):269-70.
    View in: PubMed
    Score: 0.011
  71. What causes the antiphospholipid syndrome? Curr Rheumatol Rep. 2001 Aug; 3(4):293-300.
    View in: PubMed
    Score: 0.011
  72. Which antiphospholipid antibody tests are most useful? Rheum Dis Clin North Am. 2001 Aug; 27(3):525-49.
    View in: PubMed
    Score: 0.011
  73. Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J Thromb Haemost. 2021 09; 19(9):2268-2274.
    View in: PubMed
    Score: 0.011
  74. Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care Res (Hoboken). 2021 09; 73(9):1231-1235.
    View in: PubMed
    Score: 0.011
  75. Immune Response to Enterococcus gallinarum in Lupus Patients Is Associated With a Subset of Lupus-Associated Autoantibodies. Front Immunol. 2021; 12:635072.
    View in: PubMed
    Score: 0.011
  76. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus. Lupus. 2021 Jul; 30(8):1254-1263.
    View in: PubMed
    Score: 0.011
  77. Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus. 2021 Jul; 30(8):1283-1288.
    View in: PubMed
    Score: 0.011
  78. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken). 2020 12; 72(12):1800-1808.
    View in: PubMed
    Score: 0.010
  79. Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Sci Med. 2020 10; 7(1).
    View in: PubMed
    Score: 0.010
  80. Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis Rheumatol. 2020 10; 72(10):1734-1740.
    View in: PubMed
    Score: 0.010
  81. Evaluating change in disease activity needed to reflect meaningful improvement in quality of life for clinical trials in cutaneous lupus erythematosus. J Am Acad Dermatol. 2021 Jun; 84(6):1562-1567.
    View in: PubMed
    Score: 0.010
  82. Clinical trials for the antiphospholipid syndrome. Curr Rheumatol Rep. 2000 Jun; 2(3):233-7.
    View in: PubMed
    Score: 0.010
  83. Autoantibody-positive healthy individuals with lower lupus risk display a unique immune endotype. J Allergy Clin Immunol. 2020 12; 146(6):1419-1433.
    View in: PubMed
    Score: 0.010
  84. Low frequency of flares during pregnancy and post-partum in stable lupus patients. Arthritis Res Ther. 2020 03 19; 22(1):52.
    View in: PubMed
    Score: 0.010
  85. Lupus patient decisions about clinical trial participation: a qualitative evaluation of perceptions, facilitators and barriers. Lupus Sci Med. 2020; 7(1):e000360.
    View in: PubMed
    Score: 0.010
  86. Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis Rheumatol. 2020 04; 72(4):658-666.
    View in: PubMed
    Score: 0.010
  87. Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Ann Rheum Dis. 2020 03; 79(3):356-362.
    View in: PubMed
    Score: 0.010
  88. Sex hormone binding globulins and atherosclerotic risk in systemic lupus. Lupus. 2000; 9(3):217-22.
    View in: PubMed
    Score: 0.010
  89. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2020 01; 72(1):67-77.
    View in: PubMed
    Score: 0.010
  90. Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. J Autoimmun. 2020 01; 106:102340.
    View in: PubMed
    Score: 0.010
  91. Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology (Oxford). 2019 07 01; 58(7):1259-1267.
    View in: PubMed
    Score: 0.009
  92. Immunologic findings precede rapid lupus flare after transient steroid therapy. Sci Rep. 2019 06 13; 9(1):8590.
    View in: PubMed
    Score: 0.009
  93. Antinuclear Antibody-Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care Res (Hoboken). 2019 07; 71(7):893-902.
    View in: PubMed
    Score: 0.009
  94. Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 07; 71(7):1125-1134.
    View in: PubMed
    Score: 0.009
  95. Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019 08; 71(8):1297-1307.
    View in: PubMed
    Score: 0.009
  96. Enhancement of protein S anticoagulant function by beta2-glycoprotein I, a major target antigen of antiphospholipid antibodies: beta2-glycoprotein I interferes with binding of protein S to its plasma inhibitor, C4b-binding protein. Thromb Haemost. 1999 May; 81(5):748-57.
    View in: PubMed
    Score: 0.009
  97. Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. J Rheumatol. 2020 01; 47(1):72-81.
    View in: PubMed
    Score: 0.009
  98. Longitudinal profiling of human blood transcriptome in healthy and lupus pregnancy. J Exp Med. 2019 05 06; 216(5):1154-1169.
    View in: PubMed
    Score: 0.009
  99. Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2019 02; 71(2):281-289.
    View in: PubMed
    Score: 0.009
  100. Osteopontin and Disease Activity in Patients with Recent-onset Systemic Lupus Erythematosus: Results from the SLICC Inception Cohort. J Rheumatol. 2019 05; 46(5):492-500.
    View in: PubMed
    Score: 0.009
  101. Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Ann Rheum Dis. 2019 07; 78(7):1010-1012.
    View in: PubMed
    Score: 0.009
  102. Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Hum Mol Genet. 2018 11 01; 27(21):3813-3824.
    View in: PubMed
    Score: 0.009
  103. Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care Res (Hoboken). 2018 10; 70(10):1478-1487.
    View in: PubMed
    Score: 0.009
  104. Trans-Ethnic Mapping of BANK1 Identifies Two Independent SLE-Risk Linkage Groups Enriched for Co-Transcriptional Splicing Marks. Int J Mol Sci. 2018 Aug 08; 19(8).
    View in: PubMed
    Score: 0.009
  105. A plausibly causal functional lupus-associated risk variant in the STAT1-STAT4 locus. Hum Mol Genet. 2018 07 01; 27(13):2392-2404.
    View in: PubMed
    Score: 0.009
  106. Antibodies to periodontogenic bacteria are associated with higher disease activity in lupus patients. Clin Exp Rheumatol. 2019 Jan-Feb; 37(1):106-111.
    View in: PubMed
    Score: 0.009
  107. Brief Report: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Multiple-Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis. Arthritis Rheumatol. 2018 07; 70(7):1071-1076.
    View in: PubMed
    Score: 0.009
  108. Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology (Oxford). 2018 04 01; 57(4):677-687.
    View in: PubMed
    Score: 0.009
  109. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Ann Rheum Dis. 2018 04; 77(4):549-555.
    View in: PubMed
    Score: 0.009
  110. Clinical trial parameters that influence outcomes in lupus trials that use the systemic lupus erythematosus responder index. Rheumatology (Oxford). 2018 01 01; 57(1):125-133.
    View in: PubMed
    Score: 0.009
  111. Contribution of Socioeconomic Status to Racial/Ethnic Disparities in Adverse Pregnancy Outcomes Among Women With Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2018 02; 70(2):230-235.
    View in: PubMed
    Score: 0.009
  112. Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study. Arthritis Res Ther. 2017 12 22; 19(1):287.
    View in: PubMed
    Score: 0.009
  113. Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. J Rheumatol. 2018 04; 45(4):456-464.
    View in: PubMed
    Score: 0.009
  114. Clinical and Serologic Features in Patients With Incomplete Lupus Classification Versus Systemic Lupus Erythematosus Patients and Controls. Arthritis Care Res (Hoboken). 2017 12; 69(12):1780-1788.
    View in: PubMed
    Score: 0.008
  115. Transancestral mapping and genetic load in systemic lupus erythematosus. Nat Commun. 2017 07 17; 8:16021.
    View in: PubMed
    Score: 0.008
  116. High prevalence of antiphospholipid antibodies in patients taking procainamide. J Rheumatol. 1997 Jun; 24(6):1083-8.
    View in: PubMed
    Score: 0.008
  117. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol. 2017 Jun 07; 12(6):940-946.
    View in: PubMed
    Score: 0.008
  118. Brief Report: Longitudinal Patterns of Response to Standard of Care Therapy for Systemic Lupus Erythematosus: Implications for Clinical Trial Design. Arthritis Rheumatol. 2017 04; 69(4):785-790.
    View in: PubMed
    Score: 0.008
  119. Gene Expression and Pharmacodynamic Changes in 1,760 Systemic Lupus Erythematosus Patients From Two Phase III Trials of BAFF Blockade With Tabalumab. Arthritis Rheumatol. 2017 03; 69(3):643-654.
    View in: PubMed
    Score: 0.008
  120. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017 Sep; 26(10):1051-1059.
    View in: PubMed
    Score: 0.008
  121. Pathways of impending disease flare in African-American systemic lupus erythematosus patients. J Autoimmun. 2017 03; 78:70-78.
    View in: PubMed
    Score: 0.008
  122. Anifrolumab, an Anti-Interferon-a Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus. Arthritis Rheumatol. 2017 02; 69(2):376-386.
    View in: PubMed
    Score: 0.008
  123. Autoantibody-Positive Healthy Individuals Display Unique Immune Profiles That May Regulate Autoimmunity. Arthritis Rheumatol. 2016 10; 68(10):2492-502.
    View in: PubMed
    Score: 0.008
  124. Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. Ann Rheum Dis. 2017 Mar; 76(3):534-542.
    View in: PubMed
    Score: 0.008
  125. Epigenetic Reprogramming in Naive CD4+ T Cells Favoring T Cell Activation and Non-Th1 Effector T Cell Immune Response as an Early Event in Lupus Flares. Arthritis Rheumatol. 2016 09; 68(9):2200-9.
    View in: PubMed
    Score: 0.008
  126. Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes. Arthritis Rheumatol. 2016 08; 68(8):1964-9.
    View in: PubMed
    Score: 0.008
  127. A Longitudinal Analysis of Outcomes of Lupus Nephritis in an International Inception Cohort Using a Multistate Model Approach. Arthritis Rheumatol. 2016 08; 68(8):1932-44.
    View in: PubMed
    Score: 0.008
  128. X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis Rheumatol. 2016 05; 68(5):1290-1300.
    View in: PubMed
    Score: 0.008
  129. Long-Term Safety and Efficacy of Epratuzumab in the Treatment of Moderate-to- Severe Systemic Lupus Erythematosus: Results From an Open-Label Extension Study. Arthritis Care Res (Hoboken). 2016 Apr; 68(4):534-43.
    View in: PubMed
    Score: 0.008
  130. Sifalimumab, an anti-interferon-a monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2016 Nov; 75(11):1909-1916.
    View in: PubMed
    Score: 0.008
  131. The antiphospholipid syndrome and SLE: is there a clue in the link between complement and coagulation? Lupus. 1996 Feb; 5(1):6-10.
    View in: PubMed
    Score: 0.007
  132. Decreased SMG7 expression associates with lupus-risk variants and elevated antinuclear antibody production. Ann Rheum Dis. 2016 Nov; 75(11):2007-2013.
    View in: PubMed
    Score: 0.007
  133. Selection of a gene for apolipoprotein A1 using autoantibodies from a patient with systemic lupus erythematosus. Arthritis Rheum. 1995 Nov; 38(11):1655-9.
    View in: PubMed
    Score: 0.007
  134. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.007
  135. Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clin Immunol. 2015 Dec; 161(2):157-62.
    View in: PubMed
    Score: 0.007
  136. The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2016 Feb; 55(2):252-62.
    View in: PubMed
    Score: 0.007
  137. Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trials. Arthritis Res Ther. 2015 Aug 20; 17:215.
    View in: PubMed
    Score: 0.007
  138. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med. 2015 Aug 04; 163(3):153-63.
    View in: PubMed
    Score: 0.007
  139. Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Rheumatol. 2015 Jul; 67(7):1837-47.
    View in: PubMed
    Score: 0.007
  140. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-a) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. 2016 Jan; 75(1):196-202.
    View in: PubMed
    Score: 0.007
  141. Renal involvement in lupus is characterized by unique DNA methylation changes in naïve CD4+ T cells. J Autoimmun. 2015 Jul; 61:29-35.
    View in: PubMed
    Score: 0.007
  142. Ribosomal and immune transcripts associate with relapse in acquired ADAMTS13-deficient thrombotic thrombocytopenic purpura. PLoS One. 2015; 10(2):e0117614.
    View in: PubMed
    Score: 0.007
  143. Genetic association of CD247 (CD3?) with SLE in a large-scale multiethnic study. Genes Immun. 2015 Mar; 16(2):142-50.
    View in: PubMed
    Score: 0.007
  144. Electrocardiographic findings in systemic lupus erythematosus: data from an international inception cohort. Arthritis Care Res (Hoboken). 2015 Jan; 67(1):128-35.
    View in: PubMed
    Score: 0.007
  145. Differential expression of the transcription factor ARID3a in lupus patient hematopoietic progenitor cells. J Immunol. 2015 Feb 01; 194(3):940-9.
    View in: PubMed
    Score: 0.007
  146. Disease activity in systemic lupus erythematosus correlates with expression of the transcription factor AT-rich-interactive domain 3A. Arthritis Rheumatol. 2014 Dec; 66(12):3404-12.
    View in: PubMed
    Score: 0.007
  147. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014 Nov; 66(11):1653-61.
    View in: PubMed
    Score: 0.007
  148. The IRF5-TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Hum Mol Genet. 2015 Jan 15; 24(2):582-96.
    View in: PubMed
    Score: 0.007
  149. Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Ann Rheum Dis. 2016 Jan; 75(1):242-52.
    View in: PubMed
    Score: 0.007
  150. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014 Aug; 66(8):1167-76.
    View in: PubMed
    Score: 0.007
  151. Proinflammatory adaptive cytokine and shed tumor necrosis factor receptor levels are elevated preceding systemic lupus erythematosus disease flare. Arthritis Rheumatol. 2014 Jul; 66(7):1888-99.
    View in: PubMed
    Score: 0.007
  152. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Ann Rheum Dis. 2015 Sep; 74(9):1706-13.
    View in: PubMed
    Score: 0.007
  153. Dynamic state of beta 2 integrin phosphorylation: regulation of neutrophil aggregation involves a phosphatase-dependent pathway. Clin Immunol Immunopathol. 1994 May; 71(2):216-22.
    View in: PubMed
    Score: 0.007
  154. Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription. Am J Hum Genet. 2014 Apr 03; 94(4):586-98.
    View in: PubMed
    Score: 0.007
  155. American College of Rheumatology criteria at inception, and accrual over 5 years in the SLICC inception cohort. J Rheumatol. 2014 May; 41(5):875-80.
    View in: PubMed
    Score: 0.007
  156. Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2015 Aug; 74(8):1530-6.
    View in: PubMed
    Score: 0.007
  157. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol. 2014 Feb; 66(2):390-6.
    View in: PubMed
    Score: 0.007
  158. Headache in systemic lupus erythematosus: results from a prospective, international inception cohort study. Arthritis Rheum. 2013 Nov; 65(11):2887-97.
    View in: PubMed
    Score: 0.006
  159. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. J Rheumatol. 2014 Feb; 41(2):300-9.
    View in: PubMed
    Score: 0.006
  160. Preferential binding to Elk-1 by SLE-associated IL10 risk allele upregulates IL10 expression. PLoS Genet. 2013; 9(10):e1003870.
    View in: PubMed
    Score: 0.006
  161. Herpes zoster vaccination in SLE: a pilot study of immunogenicity. J Rheumatol. 2013 Nov; 40(11):1875-80.
    View in: PubMed
    Score: 0.006
  162. ABIN1 dysfunction as a genetic basis for lupus nephritis. J Am Soc Nephrol. 2013 Nov; 24(11):1743-54.
    View in: PubMed
    Score: 0.006
  163. PTPN22 association in systemic lupus erythematosus (SLE) with respect to individual ancestry and clinical sub-phenotypes. PLoS One. 2013; 8(8):e69404.
    View in: PubMed
    Score: 0.006
  164. Reply: To PMID 22556106. Arthritis Care Res (Hoboken). 2013 Aug; 65(8):1392.
    View in: PubMed
    Score: 0.006
  165. Trans-ancestral studies fine map the SLE-susceptibility locus TNFSF4. PLoS Genet. 2013; 9(7):e1003554.
    View in: PubMed
    Score: 0.006
  166. Variable association of reactive intermediate genes with systemic lupus erythematosus in populations with different African ancestry. J Rheumatol. 2013 Jun; 40(6):842-9.
    View in: PubMed
    Score: 0.006
  167. Genome-wide DNA methylation study suggests epigenetic accessibility and transcriptional poising of interferon-regulated genes in naïve CD4+ T cells from lupus patients. J Autoimmun. 2013 Jun; 43:78-84.
    View in: PubMed
    Score: 0.006
  168. Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study. J Rheumatol. 2013 May; 40(5):579-89.
    View in: PubMed
    Score: 0.006
  169. Monitoring cartilage loss in the hands and wrists in rheumatoid arthritis with magnetic resonance imaging in a multi-center clinical trial: IMPRESS (NCT00425932). Arthritis Res Ther. 2013 Mar 20; 15(2):R44.
    View in: PubMed
    Score: 0.006
  170. MicroRNA-3148 modulates allelic expression of toll-like receptor 7 variant associated with systemic lupus erythematosus. PLoS Genet. 2013; 9(2):e1003336.
    View in: PubMed
    Score: 0.006
  171. Admixture mapping in lupus identifies multiple functional variants within IFIH1 associated with apoptosis, inflammation, and autoantibody production. PLoS Genet. 2013; 9(2):e1003222.
    View in: PubMed
    Score: 0.006
  172. Circulating levels of soluble MER in lupus reflect M2c activation of monocytes/macrophages, autoantibody specificities and disease activity. Arthritis Res Ther. 2013; 15(6):R212.
    View in: PubMed
    Score: 0.006
  173. Association of two independent functional risk haplotypes in TNIP1 with systemic lupus erythematosus. Arthritis Rheum. 2012 Nov; 64(11):3695-705.
    View in: PubMed
    Score: 0.006
  174. Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian-European populations. Arthritis Rheum. 2012 Nov; 64(11):3687-94.
    View in: PubMed
    Score: 0.006
  175. Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Ann Rheum Dis. 2013 Aug; 72(8):1308-14.
    View in: PubMed
    Score: 0.006
  176. Fine mapping of Xq28: both MECP2 and IRAK1 contribute to risk for systemic lupus erythematosus in multiple ancestral groups. Ann Rheum Dis. 2013 Mar; 72(3):437-44.
    View in: PubMed
    Score: 0.006
  177. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012 Aug; 64(8):2677-86.
    View in: PubMed
    Score: 0.006
  178. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum. 2012 Jul; 64(7):2311-8.
    View in: PubMed
    Score: 0.006
  179. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012 Jun; 64(6):797-808.
    View in: PubMed
    Score: 0.006
  180. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis. 2012 Nov; 71(11):1833-8.
    View in: PubMed
    Score: 0.006
  181. Variation in the ICAM1-ICAM4-ICAM5 locus is associated with systemic lupus erythematosus susceptibility in multiple ancestries. Ann Rheum Dis. 2012 Nov; 71(11):1809-14.
    View in: PubMed
    Score: 0.006
  182. A functional haplotype of UBE2L3 confers risk for systemic lupus erythematosus. Genes Immun. 2012 Jul; 13(5):380-7.
    View in: PubMed
    Score: 0.006
  183. Disease-specific patient reported outcome tools for systemic lupus erythematosus. Semin Arthritis Rheum. 2012 Aug; 42(1):56-65.
    View in: PubMed
    Score: 0.006
  184. Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Ann Rheum Dis. 2012 Sep; 71(9):1502-9.
    View in: PubMed
    Score: 0.006
  185. Identification of IRF8, TMEM39A, and IKZF3-ZPBP2 as susceptibility loci for systemic lupus erythematosus in a large-scale multiracial replication study. Am J Hum Genet. 2012 Apr 06; 90(4):648-60.
    View in: PubMed
    Score: 0.006
  186. Sex-specific differences in the relationship between genetic susceptibility, T cell DNA demethylation and lupus flare severity. J Autoimmun. 2012 May; 38(2-3):J216-22.
    View in: PubMed
    Score: 0.006
  187. Evidence for gene-gene epistatic interactions among susceptibility loci for systemic lupus erythematosus. Arthritis Rheum. 2012 Feb; 64(2):485-92.
    View in: PubMed
    Score: 0.006
  188. Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis. J Rheumatol. 2012 Mar; 39(3):510-5.
    View in: PubMed
    Score: 0.006
  189. Evaluation of TRAF6 in a large multiancestral lupus cohort. Arthritis Rheum. 2012 Jun; 64(6):1960-9.
    View in: PubMed
    Score: 0.006
  190. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken). 2012 Jan; 64(1):132-7.
    View in: PubMed
    Score: 0.006
  191. Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun. 2012 Apr; 13(3):232-8.
    View in: PubMed
    Score: 0.006
  192. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011 Dec; 63(12):3918-30.
    View in: PubMed
    Score: 0.006
  193. B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels. Arthritis Rheum. 2011 Dec; 63(12):3931-41.
    View in: PubMed
    Score: 0.006
  194. Analysis of autosomal genes reveals gene-sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Ann Rheum Dis. 2012 May; 71(5):694-9.
    View in: PubMed
    Score: 0.006
  195. IRF5 haplotypes demonstrate diverse serological associations which predict serum interferon alpha activity and explain the majority of the genetic association with systemic lupus erythematosus. Ann Rheum Dis. 2012 Mar; 71(3):463-8.
    View in: PubMed
    Score: 0.006
  196. Identification of novel genetic susceptibility loci in African American lupus patients in a candidate gene association study. Arthritis Rheum. 2011 Nov; 63(11):3493-501.
    View in: PubMed
    Score: 0.006
  197. Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK. Ann Rheum Dis. 2012 Jan; 71(1):136-42.
    View in: PubMed
    Score: 0.006
  198. Association of PPP2CA polymorphisms with systemic lupus erythematosus susceptibility in multiple ethnic groups. Arthritis Rheum. 2011 Sep; 63(9):2755-63.
    View in: PubMed
    Score: 0.006
  199. Influenza vaccination responses in human systemic lupus erythematosus: impact of clinical and demographic features. Arthritis Rheum. 2011 Aug; 63(8):2396-406.
    View in: PubMed
    Score: 0.005
  200. Phenotypic associations of genetic susceptibility loci in systemic lupus erythematosus. Ann Rheum Dis. 2011 Oct; 70(10):1752-7.
    View in: PubMed
    Score: 0.005
  201. Fine-mapping and transethnic genotyping establish IL2/IL21 genetic association with lupus and localize this genetic effect to IL21. Arthritis Rheum. 2011 Jun; 63(6):1689-97.
    View in: PubMed
    Score: 0.005
  202. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011 May; 7(5):e1002079.
    View in: PubMed
    Score: 0.005
  203. Genome-wide DNA methylation patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011 May; 6(5):593-601.
    View in: PubMed
    Score: 0.005
  204. The genetics of systemic lupus erythematosus and implications for targeted therapy. Ann Rheum Dis. 2011 Mar; 70 Suppl 1:i37-43.
    View in: PubMed
    Score: 0.005
  205. Autoantibodies in systemic lupus erythematosus: comparison of historical and current assessment of seropositivity. Lupus. 2011 Mar; 20(3):250-5.
    View in: PubMed
    Score: 0.005
  206. SF-36 summary and subscale scores are reliable outcomes of neuropsychiatric events in systemic lupus erythematosus. Ann Rheum Dis. 2011 Jun; 70(6):961-7.
    View in: PubMed
    Score: 0.005
  207. Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus. Nat Genet. 2011 Mar; 43(3):253-8.
    View in: PubMed
    Score: 0.005
  208. Evaluation of the TREX1 gene in a large multi-ancestral lupus cohort. Genes Immun. 2011 Jun; 12(4):270-9.
    View in: PubMed
    Score: 0.005
  209. Identification of a systemic lupus erythematosus susceptibility locus at 11p13 between PDHX and CD44 in a multiethnic study. Am J Hum Genet. 2011 Jan 07; 88(1):83-91.
    View in: PubMed
    Score: 0.005
  210. International consensus for a definition of disease flare in lupus. Lupus. 2011 Apr; 20(5):453-62.
    View in: PubMed
    Score: 0.005
  211. Two pathways of CD11b/CD18-mediated neutrophil aggregation with different involvement of protein kinase C-dependent phosphorylation. J Immunol. 1990 Oct 15; 145(8):2608-15.
    View in: PubMed
    Score: 0.005
  212. The lupus family registry and repository. Rheumatology (Oxford). 2011 Jan; 50(1):47-59.
    View in: PubMed
    Score: 0.005
  213. An assessment of disease flare in patients with systemic lupus erythematosus: a comparison of BILAG 2004 and the flare version of SELENA. Ann Rheum Dis. 2011 Jan; 70(1):54-9.
    View in: PubMed
    Score: 0.005
  214. TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus. Arthritis Res Ther. 2010; 12(4):R146.
    View in: PubMed
    Score: 0.005
  215. The role of genetic variation near interferon-kappa in systemic lupus erythematosus. J Biomed Biotechnol. 2010; 2010.
    View in: PubMed
    Score: 0.005
  216. Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2010 Jun; 62(6):881-7.
    View in: PubMed
    Score: 0.005
  217. Clinical trials in lupus: what have we learned so far? Rheumatology (Oxford). 2010 Jun; 49(6):1025-7.
    View in: PubMed
    Score: 0.005
  218. ITGAM coding variant (rs1143679) influences the risk of renal disease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry. Ann Rheum Dis. 2010 Jul; 69(7):1329-32.
    View in: PubMed
    Score: 0.005
  219. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum. 2009 Sep 15; 61(9):1168-78.
    View in: PubMed
    Score: 0.005
  220. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009 Sep 15; 61(9):1143-51.
    View in: PubMed
    Score: 0.005
  221. A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum. 2009 Aug; 60(8):2402-7.
    View in: PubMed
    Score: 0.005
  222. Plasma from systemic lupus patients compromises cholesterol homeostasis: a potential mechanism linking autoimmunity to atherosclerotic cardiovascular disease. Rheumatol Int. 2010 Mar; 30(5):591-8.
    View in: PubMed
    Score: 0.005
  223. Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun. 2009 Jul; 10(5):446-56.
    View in: PubMed
    Score: 0.005
  224. Evaluation of C1q genomic region in minority racial groups of lupus. Genes Immun. 2009 Jul; 10(5):517-24.
    View in: PubMed
    Score: 0.005
  225. Genetic associations of LYN with systemic lupus erythematosus. Genes Immun. 2009 Jul; 10(5):397-403.
    View in: PubMed
    Score: 0.005
  226. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010 Mar; 69(3):529-35.
    View in: PubMed
    Score: 0.005
  227. Replication of the BANK1 genetic association with systemic lupus erythematosus in a European-derived population. Genes Immun. 2009 Jul; 10(5):531-8.
    View in: PubMed
    Score: 0.005
  228. Kallikrein genes are associated with lupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J Clin Invest. 2009 Apr; 119(4):911-23.
    View in: PubMed
    Score: 0.005
  229. Variants within MECP2, a key transcription regulator, are associated with increased susceptibility to lupus and differential gene expression in patients with systemic lupus erythematosus. Arthritis Rheum. 2009 Apr; 60(4):1076-84.
    View in: PubMed
    Score: 0.005
  230. High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum. 2009 Apr; 60(4):1085-95.
    View in: PubMed
    Score: 0.005
  231. Expression of endothelial protein C receptor in cortical peritubular capillaries associates with a poor clinical response in lupus nephritis. Rheumatology (Oxford). 2009 May; 48(5):513-9.
    View in: PubMed
    Score: 0.005
  232. Enhanced CD36 scavenger receptor expression in THP-1 human monocytes in the presence of lupus plasma: linking autoimmunity and atherosclerosis. Exp Biol Med (Maywood). 2009 Mar; 234(3):354-60.
    View in: PubMed
    Score: 0.005
  233. Evaluation of imputation-based association in and around the integrin-alpha-M (ITGAM) gene and replication of robust association between a non-synonymous functional variant within ITGAM and systemic lupus erythematosus (SLE). Hum Mol Genet. 2009 Mar 15; 18(6):1171-80.
    View in: PubMed
    Score: 0.005
  234. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther. 2008; 10(5):R109.
    View in: PubMed
    Score: 0.004
  235. Systemic lupus international collaborating clinics renal activity/response exercise: comparison of agreement in rating renal response. Arthritis Rheum. 2008 Jun; 58(6):1789-95.
    View in: PubMed
    Score: 0.004
  236. Systemic lupus international collaborating clinics renal activity/response exercise: development of a renal activity score and renal response index. Arthritis Rheum. 2008 Jun; 58(6):1784-8.
    View in: PubMed
    Score: 0.004
  237. Short-term outcome of neuropsychiatric events in systemic lupus erythematosus upon enrollment into an international inception cohort study. Arthritis Rheum. 2008 May 15; 59(5):721-9.
    View in: PubMed
    Score: 0.004
  238. Antiphospholipid antibodies and the antiphospholipid syndrome: clinical significance and treatment. Semin Thromb Hemost. 2008 Apr; 34(3):256-66.
    View in: PubMed
    Score: 0.004
  239. Autoantibodies and neuropsychiatric events at the time of systemic lupus erythematosus diagnosis: results from an international inception cohort study. Arthritis Rheum. 2008 Mar; 58(3):843-53.
    View in: PubMed
    Score: 0.004
  240. Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans. Genes Immun. 2008 Apr; 9(3):187-94.
    View in: PubMed
    Score: 0.004
  241. Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet. 2008 Feb; 40(2):204-10.
    View in: PubMed
    Score: 0.004
  242. A nonsynonymous functional variant in integrin-alpha(M) (encoded by ITGAM) is associated with systemic lupus erythematosus. Nat Genet. 2008 Feb; 40(2):152-4.
    View in: PubMed
    Score: 0.004
  243. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis. 2008 Apr; 67(4):458-61.
    View in: PubMed
    Score: 0.004
  244. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum. 2007 Jul; 56(7):2344-51.
    View in: PubMed
    Score: 0.004
  245. Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum. 2007 Jan; 56(1):265-73.
    View in: PubMed
    Score: 0.004
  246. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus. 2007; 16(6):401-9.
    View in: PubMed
    Score: 0.004
  247. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005 Dec 15; 353(24):2550-8.
    View in: PubMed
    Score: 0.004
  248. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005 Nov 24; 353(21):2219-28.
    View in: PubMed
    Score: 0.004
  249. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005 Jun 21; 142(12 Pt 1):953-62.
    View in: PubMed
    Score: 0.004
  250. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol. 2004 Dec; 31(12):2390-4.
    View in: PubMed
    Score: 0.003
  251. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004 Sep; 50(9):2858-68.
    View in: PubMed
    Score: 0.003
  252. Anti-beta 2-glycoprotein I and antiphosphatidylserine antibodies are predictors of arterial thrombosis in patients with antiphospholipid syndrome. Am J Clin Pathol. 2004 Jan; 121(1):142-9.
    View in: PubMed
    Score: 0.003
  253. Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance. Thromb Haemost. 2003 Oct; 90(4):636-41.
    View in: PubMed
    Score: 0.003
  254. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol. 2003 Jun-Dec; 10(2-4):203-11.
    View in: PubMed
    Score: 0.003
  255. Identification and characterization of a peptide mimetic that may detect a species of disease-associated anticardiolipin antibodies in patients with the antiphospholipid syndrome. Arthritis Rheum. 2003 Mar; 48(3):737-45.
    View in: PubMed
    Score: 0.003
  256. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2002 Dec; 46(12):3251-8.
    View in: PubMed
    Score: 0.003
  257. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002 Jul; 46(7):1820-9.
    View in: PubMed
    Score: 0.003
  258. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum. 2001 Jun; 44(6):1466-7.
    View in: PubMed
    Score: 0.003
  259. SR proteins are autoantigens in patients with systemic lupus erythematosus. Importance of phosphoepitopes. Arthritis Rheum. 2000 Aug; 43(8):1768-78.
    View in: PubMed
    Score: 0.003
  260. A role for the polymorphism at position 247 of the beta2-glycoprotein I gene in the generation of anti-beta2-glycoprotein I antibodies in the antiphospholipid syndrome. Arthritis Rheum. 1999 Aug; 42(8):1655-61.
    View in: PubMed
    Score: 0.002
  261. Frequency of antibodies to the cholesterol transport protein apolipoprotein A1 in patients with SLE. Lupus. 1998; 7(5):355-60.
    View in: PubMed
    Score: 0.002
  262. Differential phosphorylation of the beta2 integrin CD11b/CD18 in the plasma and specific granule membranes of neutrophils. J Leukoc Biol. 1997 Mar; 61(3):313-21.
    View in: PubMed
    Score: 0.002
  263. Staurosporine inhibits neutrophil phagocytosis but not iC3b binding mediated by CR3 (CD11b/CD18). J Immunol. 1991 May 15; 146(10):3557-62.
    View in: PubMed
    Score: 0.001
  264. Slit-scan flow cytometry of mammalian chromosomes. J Histochem Cytochem. 1979 Jan; 27(1):441-4.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.